Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761876 | 0.85 | CYP19A1 (0.80) | CYP19A1SIGMAR1HTR1AACHE | |
| SCHEMBL28733987 | 0.85 | CYP19A1 (0.80) | CYP19A1SIGMAR1HTR1AACHE | |
| SCHEMBL30275056 | 0.85 | CYP19A1 (0.80) | CYP19A1SIGMAR1HTR1AACHE | |
| SCHEMBL13851845 | 0.85 | CYP19A1 (1.00) | CYP19A1SIGMAR1HTR1A | |
| SCHEMBL450331 | 0.84 | CYP19A1 (0.57) | CYP19A1SIGMAR1HTR1A | |
| SCHEMBL6827906 | 0.81 | CYP19A1 (0.76) | CYP19A1 | |
| SCHEMBL6822323 | 0.81 | CYP19A1 (0.76) | CYP19A1SIGMAR1ACHE | |
| SCHEMBL6827752 | 0.79 | CYP19A1 (0.77) | CYP19A1ACHE | |
| SCHEMBL10033952 | 0.77 | SIGMAR1 (0.70) | CYP19A1SIGMAR1HTR1AACHE | |
| SCHEMBL7247938 | 0.76 | CYP19A1 (0.70) | CYP19A1SIGMAR1HTR1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028110-B1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6559157-B2 | Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-06 | — | — | US | disclosed |
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1028110-A1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | Yukijirushi Nyugyo Kabushiki Kaisha (JP) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | CYP19A1, HSD17B11, CYP17A1 | CYP19A1 1/4885SIGMAR1 4364/4885HTR1A 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.